We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$98.4M
Cap. Flow %
-1.69%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17
Avg Time Held Equity + Options
4.5 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.4 quarters
Avg Time Held Equity only
5.5 quarters
Top 10 Avg Time Held Equity only
6.1 quarters
Top 20 Avg Time Held Equity only
7.1 quarters

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY icon
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC icon
BeOne Medicines Ltd
ONC
+$13M
4
BLUE icon
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.97%
4 Miscellaneous 13.15%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LRMR icon
76
Larimar Therapeutics
LRMR
$277M
$3.52M 0.06%
83,333
– –
2016 Q4
3 quarters
SIOX
77
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.44M 0.06%
62,500
+40,625
+186% +$6.85M
2016 Q3
4 quarters
BCRX icon
78
BioCryst Pharmaceuticals
BCRX
$2.18B
$3.41M 0.06%
650,000
-200,000
-24% -$1.02M
2017 Q1
2 quarters
TSRO
79
CALL
DELISTED
TESARO, Inc.
TSRO
$3.23M 0.06%
25,000
-210,000
-89% -$26.1M
2017 Q1
2 quarters
DVAX icon
80
DELISTED
Dynavax Technologies
DVAX
$3.23M 0.06%
+150,000
New +$2.37M
2017 Q3
0 quarters
JNCE
81
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$3.12M 0.05%
200,000
-50,000
-20% -$707K
2017 Q1
2 quarters
CLLS icon
82
Cellectis
CLLS
$127M
$2.85M 0.05%
100,000
– –
2015 Q1
10 quarters
CBIO icon
83
Crescent Biopharma
CBIO
$554M
$2.83M 0.05%
2,025
– –
2017 Q2
1 quarter
STML
84
DELISTED
Stemline Therapeutics, Inc.
STML
$2.77M 0.05%
250,000
– –
2017 Q1
2 quarters
CALA
85
DELISTED
Calithera Biosciences, Inc
CALA
$2.76M 0.05%
8,750
-1,250
-13% -$394K
2017 Q2
1 quarter
KYNB icon
86
Kyntra Bio
KYNB
$24.7M
$2.69M 0.05%
+2,000
New +$2.11M
2017 Q3
0 quarters
RARE icon
87
Ultragenyx Pharmaceutical
RARE
$1.53B
$2.66M 0.05%
50,000
– –
2016 Q2
5 quarters
CMRX icon
88
DELISTED
Chimerix, Inc.
CMRX
$2.63M 0.05%
500,000
– –
2016 Q3
4 quarters
BLCM
89
CALL
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.31M 0.04%
+20,000
New +$2.1M
2017 Q3
0 quarters
XNCR icon
90
Xencor
XNCR
$1.83B
$2.29M 0.04%
+100,000
New +$2.22M
2017 Q3
0 quarters
KDNY
91
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.13M 0.04%
40,000
+20,000
+100% +$1.19M
2016 Q3
4 quarters
FPRX
92
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.05M 0.04%
50,000
-100,000
-67% -$3.14M
2017 Q2
1 quarter
LUMO icon
93
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.04M 0.04%
+22,222
New +$1.7M
2017 Q3
0 quarters
CLDX icon
94
Celldex Therapeutics
CLDX
$2.35B
$1.93M 0.03%
45,000
– –
2015 Q2
9 quarters
NERV icon
95
Minerva Neurosciences
NERV
$152M
$1.91M 0.03%
31,413
– –
2016 Q3
4 quarters
BHVN icon
96
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.87M 0.03%
+50,000
New +$1.52M
2017 Q3
0 quarters
NVLN
97
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.8M 0.03%
256,400
– –
2016 Q4
3 quarters
SNDX icon
98
Syndax Pharmaceuticals
SNDX
$1.52B
$1.79M 0.03%
152,920
-147,080
-49% -$1.8M
2017 Q1
2 quarters
LUMO icon
99
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.53M 0.03%
+16,667
New +$1.28M
2017 Q3
0 quarters
KURA icon
100
Kura Oncology
KURA
$943M
$1.5M 0.03%
+100,000
New +$939K
2017 Q3
0 quarters
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group's Q3 2017 filing shows 20 new, 23 increased, 35 reduced and 17 closed positions. Its largest new stake was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M. The largest sale was Goldman Sachs, an estimated $22.6M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.